"GeneSight Enhances Depression Treatment Success, New Study Reveals"

A new post hoc analysis of the PRIME study reveals that Myriad Genetics GeneSight® test significantly improves treatment outcomes for patients with Major Depressive Disorder, leading to faster remission.

• The post hoc analysis of the PRIME study indicated that treatment guided by the GeneSight® test resulted in quicker remission for patients diagnosed with Major depressive disorder.
• Patients receiving personalized medicine through the GeneSight® test reported sustained treatment responses over six months, demonstrating the long-term efficacy of this pharmacogenomics approach.
• Conducted in Salt Lake City, the randomized controlled trial data highlights the potential of Myriad Genetics test to revolutionize mental health treatment for Major depressive disorder.